Oncology

Ali McBride, PharmD, MS, BCOP, clinical coordinator of Hematology and Oncology in the Department of Pharmacy at the University of Arizona Cancer Center and past president of the Association of Community Cancer Centers (ACCC), discusses the anticipated growth for the US biosimilar market and what the ACCC is doing to further uptake efforts.

In a trio of studies, investigators were able to demonstrate equivalency of Samsung Bioepis’ trastuzumab biosimilar in various settings.

Investigators use the HERITAGE trial findings to argue for a more precise way of measuring clinical equivalence for biosimilars.

With successful findings from a phase 3 trial of its bevacizumab biosimilar candidate, Iranian company AryoGen Pharmed is a step closer to commercialization of this product.

With 1 biosimilar launch and expanded indications for another biosimilar so far this year, Teva Pharmaceutical Industries reported higher biosimilar revenues in the first quarter of 2020.

Although Pfizer has offered a more attractive discount for its rituximab biosimilar, Teva Pharmaceutical Industries and Celltrion Healthcare have decided not to match that discount for their own rituximab biosimilar, which is more costly.

Amgen saw biosimilar competition eat a larger share of its innovator drug revenue but also earned some biosimilar pocket money of its own.

A smattering of biosimilar launches around the globe and positive results for biosimilar earnings across companies suggested a positive trend in April, despite the ongoing pandemic.

The reasons for biosimilar brand preference in a recent rituximab study were unclear, but investigators said it is clear that savings were a likely factor.

Henlius Biotech said its manufacturing facility has met European standards for production of its trastuzumab biosimilar candidate, which the company said is "a passport" for potential commericialization across the globe.

A retrospective, postmarketing study demonstrates higher incidence of joint and bone pain, neutropenia with certain filgrastim biosimilars, compared with Neupogen.

Cheryl Larson, president and chief executive officer of the Midwest Business Group on Health, discusses the sticker shock of rising specialty drug costs and how biosimilars are going to be incorporated into efforts to push back against this medical inflation.

Biosimilar pricing is not as simple as a manufacturer's stated discount to the reference product cost, according to Adam Brufsky, MD, PhD, FACP, of the University of Pittsburgh Medical Center (UPMC) in Pennsylvania.

Although the coronavirus disease 2019 (COVID-19) pandemic has put a burden on the economy and the healthcare system in particular, Kashyap Patel, MD, believes that the crisis will likely speed up biosimilar uptake in the United States.

Many additional biosimilars could be on the market by 2025, said presenters at the Academy of Managed Care Pharmacy eLearning Days virtual meeting.

Posters presented at the Academy of Managed Care Pharmacy (AMCP) eLearning Days meeting this week from April 20 to 24 reveal important data on biosimilar utilization management, switching, and affordability.

A percentage of oncology pharmacy practitioners report their guidance on biosimilars is influential with clinicians, but many feel their knowledge of biosimilars is deficient in a number of important areas.

In partnership with Samsung Bioepis, Merck has launched the trastuzumab biosimilar Ontruzant, which marks the fifth trastuzumab biosimilar available on the US market.

The Boston Medical Center Health System (BMCHS) of Massachusetts was able to achieve high adoption rates for biosimilars based on experience with a “nonbiosimilar.”

The first 3 months of 2019 saw a trio of biosimilar launches on the US market, ahead of the year-ago quarter's pace, and this came despite the disruption caused by coronavirus disease 2019.

With the launch of Mylan and Biocon’s pegfilgrastim biosimilar, Australia adds another biosimilar to its portfolio of biosimilars in circulation.

The introduction of biosimilars as anticancer therapies was preceded by a period of supportive care biosimilars. Lee S. Schwartzberg, MD, FACP, describes how he and other clinicians decide which of these agents to use.

Cancer treatments can lead to unpredictable adverse events, so a COVID-19–related measure allowing home infusion jeopardizes patient health and safety, according to the Community Oncology Alliance (COA).

Oncologist/hematologist Lee S. Schwartzberg, MD, FACP, describes some important considerations for using biosimilars in clinical practice.

Biosimilar companies may do themselves a disservice if they produce education materials that don’t address the needs of clinicians or blatently self-promote, according to Kathy Oubre, chief operations officer at Pontchartrain Cancer Center of Louisiana.

The National Comprehensive Cancer Network (NCCN) Guidelines may help get biosimilars into circulation because the NCCN will recommend them for off-label uses.

MJH Life Sciences™, owner of The Center for Biosimilars®, has acquired the Pharmacy Benefit Management Institute (PBMI), the nation’s leading provider of research and education that informs, advises, and influences the industry on drug cost management.

China’s National Medical Products Administration (NMPA) has accepted Henlius Biotech’s new drug application for its denosumab biosimilar, hlx14.

Following close on the heels of its US approval for Ruxience (rituximab), Pfizer has gained the European Commission nod and aims to launch in coming months.

The coronavirus disease 2019 (COVID-19) effect on the biosimilar industry will be deep and lasting, causing not just approval and launch delays but profound structural changes in how business is done.